These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25349138)

  • 1. Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date.
    Potter AS; Schaubhut G; Shipman M
    CNS Drugs; 2014 Dec; 28(12):1103-13. PubMed ID: 25349138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.
    Wilens TE; Decker MW
    Biochem Pharmacol; 2007 Oct; 74(8):1212-23. PubMed ID: 17689498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pozanicline for the treatment of attention-deficit/hyperactivity disorder.
    Childress A; Sallee FR
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1585-93. PubMed ID: 25196198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.
    Jucaite A; Öhd J; Potter AS; Jaeger J; Karlsson P; Hannesdottir K; Boström E; Newhouse PA; Paulsson B
    Psychopharmacology (Berl); 2014 Mar; 231(6):1251-65. PubMed ID: 23640072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
    Potter AS; Dunbar G; Mazzulla E; Hosford D; Newhouse PA
    Biol Psychiatry; 2014 Feb; 75(3):207-14. PubMed ID: 23856296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.
    Fleisher C; McGough J
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1157-63. PubMed ID: 24965900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of attention deficit hyperactivity disorder.
    Spencer T; Biederman J; Wilens T
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):77-97. PubMed ID: 10674191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha4beta2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder.
    Ueno K; Togashi H; Matsumoto M; Ohashi S; Saito H; Yoshioka M
    J Pharmacol Exp Ther; 2002 Jul; 302(1):95-100. PubMed ID: 12065705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy for adults with attention-deficit hyperactivity disorder.
    Wilens TE
    Drugs; 2003; 63(22):2395-411. PubMed ID: 14609347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder?
    Potter AS; Newhouse PA; Bucci DJ
    Behav Brain Res; 2006 Dec; 175(2):201-11. PubMed ID: 17081628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
    Weibel S; Menard O; Ionita A; Boumendjel M; Cabelguen C; Kraemer C; Micoulaud-Franchi JA; Bioulac S; Perroud N; Sauvaget A; Carton L; Gachet M; Lopez R
    Encephale; 2020 Feb; 46(1):30-40. PubMed ID: 31610922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.
    Verbeeck W; Bekkering GE; Van den Noortgate W; Kramers C
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009504. PubMed ID: 28965364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention-deficit/hyperactivity disorder: a plausible mouse model?
    Granon S; Changeux JP
    Acta Paediatr; 2006 Jun; 95(6):645-9. PubMed ID: 16754543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder.
    Potter AS; Newhouse PA
    Pharmacol Biochem Behav; 2008 Feb; 88(4):407-17. PubMed ID: 18022679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is emotional dysregulation a component of attention-deficit/hyperactivity disorder (ADHD)?].
    Villemonteix T; Purper-Ouakil D; Romo L
    Encephale; 2015 Apr; 41(2):108-14. PubMed ID: 24703785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder.
    Shytle RD; Silver AA; Wilkinson BJ; Sanberg PR
    World J Biol Psychiatry; 2002 Jul; 3(3):150-5. PubMed ID: 12478880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
    NIH Consens Statement; 1998 Nov 16-18; 16(2):1-37. PubMed ID: 10868163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.